Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CovX Research
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
CovX was a biopharmaceutical company focused on developing a new class of biotherapeutics called CovX-Bodies. This platform technology involves the site-specific conjugation of pharmacologically active peptides or small molecules to a specialized scaffold antibody, combining the half-life and distribution of an antibody with the potency of a peptide. The company's lead programs targeted metabolic diseases and oncology before it was acquired by Pfizer to bolster its biologics portfolio. Following the acquisition, CovX operated as a specialized research unit within Pfizer's BioTherapeutics Pharmaceutical Sciences group.
- Therapeutic areas
- OncologyEndocrinologyMetabolic Disorders
- Modalities
- AntibodyPeptidesRecombinant fusion protein
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on CovX Research.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CovX Research.